Jonathan H Wang1, Tracy M Downs1,2, E Jason Abel1,2, Kyle A Richards1,2, David F Jarrard3,4,5. 1. Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. 2. University of Wisconsin Carbone Comprehensive Cancer Center, Madison, WI, USA. 3. Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. jarrard@urology.wisc.edu. 4. University of Wisconsin Carbone Comprehensive Cancer Center, Madison, WI, USA. jarrard@urology.wisc.edu. 5. Environmental and Molecular Toxicology, University of Wisconsin, Madison, WI, USA. jarrard@urology.wisc.edu.
Abstract
PURPOSE OF REVIEW: This manuscript reviews contemporary literature regarding prostate cancer active surveillance (AS) protocols as well as other tools that may guide the management of biopsy frequency and assess the possibility of progression in low-risk prostate cancer. RECENT FINDINGS: There is no consensus regarding the timing of surveillance biopsies; however, an immediate repeat biopsy within 12 months of diagnosis for patients considering AS confirms patients who have favorable risk disease yet also identifies patients who were undersampled initially. Studies regarding multiparametric MRI, nomograms, and biomarkers show promise in risk stratifying and counseling patients during AS. Further studies are needed to determine if these supplemental tests can decrease the frequency of surveillance biopsies. An immediate re-biopsy can help to reduce the risk of missing clinically significant disease. Other clinical tools, including mpMRI, exist that can be used as an adjunct to counsel patients and guide a personalized discussion regarding the frequency of surveillance biopsies.
PURPOSE OF REVIEW: This manuscript reviews contemporary literature regarding prostate cancer active surveillance (AS) protocols as well as other tools that may guide the management of biopsy frequency and assess the possibility of progression in low-risk prostate cancer. RECENT FINDINGS: There is no consensus regarding the timing of surveillance biopsies; however, an immediate repeat biopsy within 12 months of diagnosis for patients considering AS confirms patients who have favorable risk disease yet also identifies patients who were undersampled initially. Studies regarding multiparametric MRI, nomograms, and biomarkers show promise in risk stratifying and counseling patients during AS. Further studies are needed to determine if these supplemental tests can decrease the frequency of surveillance biopsies. An immediate re-biopsy can help to reduce the risk of missing clinically significant disease. Other clinical tools, including mpMRI, exist that can be used as an adjunct to counsel patients and guide a personalized discussion regarding the frequency of surveillance biopsies.
Authors: Andrea Gallina; Carmen Maccagnano; Nazareno Suardi; Umberto Capitanio; Firas Abdollah; Marco Raber; Andrea Salonia; Vincenzo Scattoni; Patrizio Rigatti; Francesco Montorsi; Alberto Briganti Journal: BJU Int Date: 2011-11-17 Impact factor: 5.588
Authors: Marc A Dall'Era; Peter C Albertsen; Christopher Bangma; Peter R Carroll; H Ballentine Carter; Matthew R Cooperberg; Stephen J Freedland; Laurence H Klotz; Christopher Parker; Mark S Soloway Journal: Eur Urol Date: 2012-06-07 Impact factor: 20.096
Authors: James S Wysock; Neil Mendhiratta; Fabio Zattoni; Xiaosong Meng; Marc Bjurlin; William C Huang; Herbert Lepor; Andrew B Rosenkrantz; Samir S Taneja Journal: BJU Int Date: 2016-02-25 Impact factor: 5.588
Authors: Matthew R Cooperberg; Jeffry P Simko; Janet E Cowan; Julia E Reid; Azita Djalilvand; Satish Bhatnagar; Alexander Gutin; Jerry S Lanchbury; Gregory P Swanson; Steven Stone; Peter R Carroll Journal: J Clin Oncol Date: 2013-03-04 Impact factor: 44.544
Authors: Liam C Macleod; William J Ellis; Lisa F Newcomb; Yingye Zheng; James D Brooks; Peter R Carroll; Martin E Gleave; Raymond S Lance; Peter S Nelson; Ian M Thompson; Andrew A Wagner; John T Wei; Daniel W Lin Journal: J Urol Date: 2016-11-01 Impact factor: 7.450
Authors: J Cuzick; D M Berney; G Fisher; D Mesher; H Møller; J E Reid; M Perry; J Park; A Younus; A Gutin; C S Foster; P Scardino; J S Lanchbury; S Stone Journal: Br J Cancer Date: 2012-02-23 Impact factor: 7.640
Authors: Mieke Van Hemelrijck; Xinge Ji; Jozien Helleman; Monique J Roobol; Daan Nieboer; Chris Bangma; Mark Frydenberg; Antti Rannikko; Lui Shiong Lee; Vincent Gnanapragasam; Michael W Kattan Journal: Transl Androl Urol Date: 2021-03